Comparative Pharmacology
Head-to-head clinical analysis: EMFLAZA versus KENALOG H.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMFLAZA versus KENALOG H.
EMFLAZA vs KENALOG-H
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Triamcinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
2-40 mg (0.1-1 mL) intra-articular, intralesional, or soft tissue injection; intra-articular dose depends on joint size (large joint: 10-40 mg, medium joint: 5-25 mg, small joint: 2-10 mg); repeat every 2-3 weeks as needed.
None Documented
None Documented
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
The terminal elimination half-life is approximately 2-3 hours for triamcinolone acetonide. In the context of intra-articular or intralesional administration, the half-life at the site of action is prolonged due to slow release from the injection depot, providing sustained local effects.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Renal excretion of metabolites (primarily conjugated and unconjugated) accounts for approximately 80-90% of an administered dose, with less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder, about 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid